Core Viewpoint - MiniMed Group, Inc. has successfully closed its initial public offering (IPO) of 28 million shares at a price of $20.00 per share, raising approximately $538 million in net proceeds [1][1][1] Company Overview - MiniMed is a global leader in insulin delivery, providing advanced therapies for diabetes management in 80 countries [1][1] - The company has a full-stack, integrated ecosystem that includes insulin delivery systems, continuous glucose monitors (CGMs), algorithms, and a user-friendly app experience [1][1] IPO Details - The IPO shares began trading on the Nasdaq Global Select Market under the symbol "MMED" on March 6, 2026 [1][1] - Medtronic plc owns approximately 90.03% of MiniMed's common stock and aims to complete a separation through a split-off [1][1] - The net proceeds from the IPO will be used for general corporate purposes and to repay intercompany debt owed to Medtronic [1][1] Underwriters - The active bookrunners for the offering included Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley [1][1] - Additional joint book running managers were Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI, and Piper Sandler [1][1]

Core Viewpoint - MiniMed Group, Inc. has announced the pricing of its initial public offering (IPO) at $20.00 per share, with 28,000,000 shares available for public trading on Nasdaq starting March 6, 2026 [1] Group 1: IPO Details - The IPO is expected to close on March 9, 2026, subject to customary closing conditions [1] - MiniMed has granted underwriters a 30-day option to purchase up to 4,200,000 additional shares at the initial price [1] - Upon completion of the IPO, Medtronic is expected to hold approximately 90.03% of MiniMed, or 88.70% if the over-allotment option is fully exercised [1] Group 2: Use of Proceeds - MiniMed intends to use a portion of the net proceeds for general corporate purposes [1] - The remainder will be used to repay intercompany debt owed to Medtronic and as additional consideration for certain assets transferred to MiniMed [1] Group 3: Company Background - MiniMed is a global leader in insulin delivery, providing integrated ecosystems for diabetes management in 80 countries [1] - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company addressing significant health challenges [1]

Core Viewpoint - MiniMed Group, Inc. has launched a roadshow for its initial public offering (IPO) of 28 million shares, as part of Medtronic's plan to separate its Diabetes business into an independent public company, with an expected IPO price between $25.00 and $28.00 per share [1] Group 1: IPO Details - The IPO will consist of 28,000,000 shares of common stock, with an additional 4,200,000 shares available for underwriters to purchase within 30 days at the IPO price [1] - MiniMed plans to list its common stock on the Nasdaq Global Select Market under the symbol "MMED" [1] - Upon completion of the IPO, Medtronic will retain approximately 90.03% of MiniMed, or 88.70% if the over-allotment option is fully exercised [1] Group 2: Use of Proceeds - MiniMed intends to use a portion of the net proceeds from the IPO for general corporate purposes [1] - The remaining proceeds will be allocated to repay intercompany debt owed to Medtronic and as additional consideration for certain assets transferred to MiniMed during the separation [1] Group 3: Underwriters - The active bookrunners for the proposed offering include Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley [1] - Additional joint book running managers are Barclays, Deutsche Bank Securities, Mizuho, Wells Fargo Securities, Evercore ISI, and Piper Sandler & Co. [1] Group 4: Company Background - MiniMed is a global leader in insulin delivery, providing therapies for diabetes management in over 80 countries [1] - The company has been a pioneer in developing integrated ecosystems for insulin delivery, including systems, continuous glucose monitors (CGMs), algorithms, and user-friendly applications [1] - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges [1]